Skip to content

To assess for improvement in pulmonary functions in patients undergoing Lap cholecystectomy after irrigation of gall bladder bed with ropivacaine in comparison to normal saline

Effects of gallbladder bed irrigation with Ropivacaine vs Normal Saline on Pulmonary functions of patients undergoing laparoscopic cholecystectomy. - Nil

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/091472
Enrollment
70
Registered
2025-07-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical Health Condition 2: K802- Calculus of gallbladder without cholecystitis

Interventions

Intervention1: Ropivacaine : The patients will be randomized into two equal groups of 35 patients each. Group N: Laparoscopic cholecystectomy + Irrigation of gallbladder bed with 20 mL normal saline.

Sponsors

Moksha Joshi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The patients who were willing to participate in study and had given written, valid and informed consent. Age - 18-65 years Patients posted for laparoscopic cholecystectomy American Society of Anaesthesiologist grade I and II Patients belonging to either gender

Exclusion criteria

Exclusion criteria: Patient refusal to be part of the study. Patients with known allergies or contraindications to ropivacaine, the agent used for gallbladder bed irrigation. Pregnancy or Lactation: Pregnant or lactating patients, as the safety of ropivacaine use during pregnancy and lactation, is not established. Chronic Respiratory Conditions; Severe Cardiovascular Disease; Severe Liver or kidney disease; acute cholecystitis, choledocholithiasis History of Allergic Reactions; Current Medications; Patients currently taking medications that may interact with ropivacaine (eg Fluvoxamine, cimetidine, ciprofloxacin, ketoconazole, verapamil, amiodarone) or affect pulmonary function particularly medications that influence neuromuscular function (eg aminoglycosides, magnesium, or chronic steroids) or respiratory depression (eg Opioids, benzodiazepines, barbiturates)

Design outcomes

Primary

MeasureTime frame
FEV1, FVC, FEF 25-75Timepoint: Baseline, 6 hours, 8 hours, 12 hours, 24 hours

Secondary

MeasureTime frame
Visual Analog Scale, BHT, SBC, Cough test Timepoint: Baseline, 6hours, 8 hours, 12 hours, 24 hours

Countries

India

Contacts

Public ContactMoksha Joshi

Grant Government Medical College

Pathadepoornima@rediffmail.com9850961195

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026